Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-25
2008-07-29
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S052000, C536S022100, C536S026100, C536S027100, C536S027200
Reexamination Certificate
active
07405204
ABSTRACT:
Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.
REFERENCES:
patent: 4107288 (1978-08-01), Oppenheim et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5607915 (1997-03-01), Patton
patent: 5738985 (1998-04-01), Miles et al.
patent: 5739002 (1998-04-01), De Francesco et al.
patent: 5759795 (1998-06-01), Jubin et al.
patent: 5861267 (1999-01-01), Su
patent: 6030785 (2000-02-01), Katze et al.
patent: 6228576 (2001-05-01), Delvecchio
patent: 6479651 (2002-11-01), Seela et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 7144868 (2006-12-01), Roberts et al.
patent: 7151089 (2006-12-01), Roberts et al.
patent: 7157434 (2007-01-01), Keicher et al.
patent: 7169918 (2007-01-01), Roberts et al.
patent: 7202223 (2007-04-01), Roberts et al.
patent: 7244713 (2007-07-01), Roberts et al.
patent: 2006/0111311 (2006-05-01), Keicher et al.
patent: 2006/0194749 (2006-08-01), Keicher et al.
patent: WO 97/12033 (1997-04-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 2004/007512 (2004-01-01), None
patent: WO 2004/014313 (2004-02-01), None
patent: WO 2004/014852 (2004-02-01), None
patent: WO 2004/028481 (2004-04-01), None
patent: WO 2005/003147 (2005-01-01), None
patent: WO 2005/024268 (2005-06-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, p. 596.
Bartholomeusz, et al., “Hepatitis C Virus (HCV) RNA polymerase assay using cloned HCV non-structural proteins.” Antiviral Therapy, 1996, 1 (supp. 4), 18-24.
Beaulieu, P.L. and Tsantrizos, Y. S., “Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.” Curr. Opin. Investig. Drugs 2004, 5, 838-50.
Conglatu, et al., “Novel Potential Anticancer Naphthyl Phosphoramidates of BVdU: Separation of Diastereoisomers and Assignment of the Absolute Configuration of the Phosphorous Center.” J. Med. Chem., 2006, 49, 452-55.
Cooperwood, J. S., et al., “Nucleoside and Nucleotide prodrugs” in Ed(s) Chu, C. K. Recent Advances in Nucleosides (2002), 92-147.
Ferrari, et al., “Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed inEscherichia coli.” J. Viro., 1999, 73, 1649-54.
Fried, et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.” N. Engl. J. Med., 2002, 347, 975-82.
Griffith, et al., “HCV Antiviral Agents.” Ann. Rep. Med. Chem. 2004, 39, 223-37.
Gudmundsson, et al., “Phosphoramidate protides of carbocyclic 2′,3′-dideoxy-2′,3′-didehydro-7-deazaandenosine with potent activity against HIV and HBV.” Nucleosides Nucleotides Nucleic Acids, 2004, 23(12), 1929-37..
Hoofnagle, “Hepatitis C: the clinical spectrum of disease.” Hepatology 1997, 26, 15S-20S.
Horsmans, et al., “Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection.” Hepatology, 2005, 42, 724-31.
Hutchinson, D.W. (Ed. Leroy B. Townsend) “The Synthesis, Reaction and Properties of Nucleoside Mono-, Di-, and Triphosphates, and Nucleosides with Changes in the Phosphoryl Residue” Chemistry of Nucleosides and Nucleotides, Plenum Press, 1991, 2.
Ishii, et al., “Expression of hepatitis C virus NS5B protein: characterization of its RNA polymerase activity and RNA binding,” Hepatology, 1999, 29, 1227-35.
Lohmann, et al., “Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.” Science, 1999, 285, 110-13.
Lohmann, et al., “Selective Stimulation of Hepatitis C Virus and Pestivirus NS5B RNA Polymerase Activity by GTP.” J. Bio. Chem., 1999, 274, 10807-15.
McGulgan, et al., “Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin.” Bioorganic & Medicinal Chem. 2005, 13, 3219-27.
Meier, C., et al., Synlett 1998, 3, 233-42.
Moriishi and Matsuura, “Mechanisms of hepatitis C virus infection.” Antivir. Chem. Chemother. 2003, 14, 285-97.
Ni, Z. J. and Wagman, A. S., “Progress and development of small molecule HCV antivirals.” Curr. Opin. Drug Discov. Devel. 2004, 7, 446-59.
Prakash, et al., “Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5′-monophosphates as inhibitors of hepatitis C virus RNA replication.” J. Med. Chem., 2005, 48(4), 1199-1210.
Saunders and Raybuck, “Inosine Monophosphate Dehydrogenase: Consideration of Structure, Kinetics and Therapeutic Potential.” Ann. Rep. Med. Chem., 2000, 35, 201-10.
Szabo, et al., “Viral hepatitis: new data on hepatitis C infection.” Pathol. Oncol. Res. 2003, 9, 215-221.
Thomson and Finch, Clin Microbial Infect. 2005, 11, 86-94.
Wagner, C., et al., “Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides.” Medicinal Research Reviews 2000, 20(6), 417-451.
Watashi, et al., “Cytophilin B is a functional regulator of hepatitis C virus RNA polymerase.” Molecular Cell, 2005, 19, 111-122.
Yamashita, et al., “RNA-dependent RNA Polymerase Activity of the Soluble Recombinant Hepatitis C Virus NS5B Protein Truncated at the C-terminal Region.” J. Bio. Chem., 1998, 273, 15479-86.
Zemlicka, J., et al., “Lipophilic phosphoramidates as antiviral pronucleotides.” Biochimica et Biophysica Acta (2002), 158(2-3), 276-286.
Dyatkina Natalia B.
Griffith Ronald Conrad
Prhavc Marija
Roberts Christopher D.
Foley & Lardner LLP
Genelabs Technologies, Inc.
Jiang Shaojia Anna
McIntosh, III Traviss C
Yang Junrui
LandOfFree
Nucleoside compounds for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleoside compounds for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside compounds for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966052